The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Treatment options for patients with WM in the third‑line setting
Stephen Ansell
Jorge Castillo
Christian Buske
Monique MinnemaOn behalf of the International Waldenstrom's Macroglobulinemia Foundation (IWMF), the Lymphoma Hub was pleased to speak with Stephen Ansell, Mayo Clinic, Rochester, US, who chaired a discussion on treatment options for patients with Waldenstrom's macroglobulinemia (WM) in the third‑line setting. This discussion also featured contributions from Christian Buske, Monique Minnema, and Jorge Castillo.
Treatment options for patients with WM in the third‑line setting
The main topics discussed included:
-
Ongoing clinical trials for the treatment of WM
-
Treatment-related toxicities of concern
-
Important factors to consider when choosing treatment
-
Treatment preferences and important clinical endpoints
Buske begins by discussing the available options for treating patients with WM in the third-line setting. The panel notes that approved treatments for the third-line are very limited and treatment approaches include either repeating initial therapies or referring patients to clinical trials. The panel discusses ongoing clinical trials, highlighting the latest data for Bruton’s tyrosine kinase inhibitors, BCL-2 inhibitors, novel nuclear medicines such as iopofosine, and combination therapies for the treatment of WM. The panel also discusses the possible use of immunotherapies, including bispecific antibodies and CAR T-cell therapies for the treatment of patients with WM, and emphasize the importance of gaining data specifically in WM. Finally, Castillo discusses the positioning of autologous transplants in current clinical practice and whether strategies to retreat patients with prior lines of therapies are still warranted given the number of emerging therapies for WM.
The International Waldenstrom's Macroglobulinemia Foundation (IWMF) and the Lymphoma Hub are working in collaboration for patients with Waldenstrom's macroglobulinemia. This initiative aims to increase awareness of Waldenstrom's macroglobulinemia among healthcare professionals, patients, caregivers, and the patient advocacy community.
This initiative is funded by Cellectar Biosciences. All content is developed independently by SES in collaboration with an expert steering committee; funders are allowed no direct influence on the content of the hub.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
